Effectiveness of Ankaferd BloodStopper in Prophylaxis and Treatment of Oral Mucositis in Childhood Cancers Evaluated with Plasma Citrulline Levels

Patıroğlu, Türkan; Şahin, Nagihan Erdoğ; Ünal, Ekrem; Kendirci, Mustafa; Karakükçü, Musa; Özdemır, Mehmet Akif

doi:10.4274/tjh.2017.0320

Cited by 11 publications

(14 citation statements)

References 5 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This protein complex mainly depends on the interplay between ABS and blood proteins, particularly with fibrinogen-gamma [7] . In addition to these diverse biological activities, ABS also have substantial anti-inflammatory and wound-healing properties [13] , [14] , [18] , [19] , [45] . Although the exact pathophysiology underlying the unique effect of ABS remains an area of active investigation, the anti-inflammatory effect of ABS is reported to be based on the effect of proinflammatory cytokines including IL-6, IL-1β and TNF-α.…”

Section: Evaluation and Discussion Of The Hypothesismentioning

confidence: 99%

“…There are preliminary evidence that ABS has in vitro anti-viral actions on the Bovine Herpes virus type 1 (BHV-1) [13] as well as other established anti-infective properties in a wide variety of pathogens [11] , [12] , [13] , [16] , [17] . Most importantly, topical ABS applications for severe oral mucositis in patients with pediatric and adult cancer receiving chemotherapy/ radiotherapy [18] , [19] and mucosal healing of the pulmonary tissue in lung-bleeding patients [14] demonstrated the efficacy and safety of the drug for mucosal disease control in clinical backgrounds. Therefore, we herein hypothesize that ABS could be a possible topical drug candidate for the management of COVID-19-induced mucositis based on its pharmacobiology [5] , [6] , [7] and the nature of the SARS-CoV-2 [20] , [21] induced widespread oropharyngeal and pulmonary mucosal damages.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content

Beyazıt

Tanoğlu³

et al. 2020

Medical Hypotheses

View full text Add to dashboard Cite

COVID-19 due to the SARS-CoV-2 infection is a multi-systemic immune syndrome affecting mainly the lungs, oropharyngeal region, and other vascular endothelial beds. There are tremendous ongoing efforts for the aim of developing drugs against the COVID-19 syndrome-associated inflammation. However, currently no specific medicine is present for the absolute pharmacological cure of COVID-19 mucositis. The re-purposing/re-positioning of already existing drugs is a very important strategy for the management of ongoing pandemy since the development of a new drug needs decades. Apart from altering angiotensin signaling pathways, novel drug candidates for re-purposing comprise medications shall target COVID-19 pathobiology, including pharmaceutical formulations that antagonize proteinase-activated receptors (PARs), mainly PAR-1. Activation of the PAR-1, mediators and hormones impact on the hemostasis, endothelial activation, alveolar epithelial cells and mucosal inflammatory responses which are the essentials of the COVID-19 pathophysiology. In this context, Ankaferd hemostat (Ankaferd Blood Stopper, ABS) which is an already approved hemostatic agent affecting via vital erythroid aggregation and fibrinogen gamma could be a potential topical remedy for the mucosal management of COVID-19. ABS is a clinically safe and effective topical hemostatic agent of plant origin capable of exerting pleiotropic effects on the endothelial cells, angiogenesis, cell proliferation and vascular dynamics. ABS had been approved as a topically applied hemostatic agent for the management of post-surgical/dental bleedings and healing of infected inflammatory mucosal wounds. The anti-inflammatory and proteinase-activated receptor axis properties of ABS with a considerable amount of oestrogenic hormone presence highlight this unique topical hemostatic drug regarding the clinical re-positioning for COVID-19-associated mucositis. Topical ABS as a biological response modifier may lessen SARS-CoV-2 associated microthrombosis, endothelial dysfunction, oropharyngeal inflammation and mucosal lung damage. Moreover, PAR-1 inhibition ability of ABS might be helpful for reducing the initial virus propagation and mocasal spread of COVID-19.

show abstract

Section: Evaluation and Discussion Of The Hypothesismentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content

Beyazıt

Tanoğlu³

et al. 2020

Medical Hypotheses

View full text Add to dashboard Cite

show abstract

“…Their findings indicated that ABS protects against intestinal damage due to its antioxidant and anti-inflammatory properties. 15 In a clinical study, Patiroglu et al 16 disclosed the mucosal healing effects of ABS. ABS is effective in the prophylaxis and treatment of oral mucositis secondary to chemotherapy in childhood cancers.…”

Section: Discussionmentioning

confidence: 99%

Effective Ankaferd Hemostat Treatment For Severe Intractable Chronic Deep Leg Ulcer Associated With Behçet’s Disease

Çiftçiler

Haznedaroğlu

2019

Arch Rheumatol

View full text Add to dashboard Cite

“…In a study, the efficacy of ABS in prophylaxis and oral mucositis treatment in patients receiving chemotherapy in childhood was evaluated. ABS was thought to be effective in prophylaxis and treatment of oral mucositis secondary to chemotherapy in childhood cancers [76].…”

Section: The Usage Of Abs In Infectionsmentioning

confidence: 99%

Ankaferd hemostat: from molecules to medicine

Çiftçiler

Haznedaroğlu

2020

Turk J Med Sci

View full text Add to dashboard Cite

Ankaferd hemostat (ABS; Ankaferd Blood Stopper®, İstanbul, Turkey) is a hemostatic agent having an impact on red blood cell–fibrinogen interactions. The hemostatic effect of ABS depends upon the quick promotion of a protein network, particularly fibrinogen gamma, in relation to the erythrocyte aggregation. The entire physiological process involves ABS-induced formation of the protein network by vital erythrocyte aggregation. Vital erythrocyte aggregation occurs with the spectrine, ankyrin, and actin proteins on the membrane of the red blood cells. ABS notably affects cell metabolism and cell cycle mechanisms. Meanwhile, ABS has antiproliferative effects on cancer cells. The aim of this review is to assess molecular basis of ABS as a hemostatic drug. The literature search on ABS was performed in PubMed, Web of Science (SCI expanded), and Scopus with particular focus on the studies of molecular basis of ABS, in vivo research, case series, and controlled randomized clinical studies. Current perspective for the utilization of ABS is to provide hemostasis with accelerating wound healing. Future controlled trials are needed to elucidate the pleiotropic clinical effects of ABS such as antineoplastic, antiinflammatory, antiinfective, antifungal, and antioxidative effects.

show abstract

Effectiveness of Ankaferd BloodStopper in Prophylaxis and Treatment of Oral Mucositis in Childhood Cancers Evaluated with Plasma Citrulline Levels

Cited by 11 publications

References 5 publications

Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content

Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content

Effective Ankaferd Hemostat Treatment For Severe Intractable Chronic Deep Leg Ulcer Associated With Behçet’s Disease

Ankaferd hemostat: from molecules to medicine

Contact Info

Product

Resources

About